Redlight Guide

Hair growth / androgenetic alopecia

Red light therapy for hair growth and androgenetic alopecia

Evidence for low-level light and laser therapy in pattern hair loss, with a focus on what is and is not relevant to general red light panels.

Study count

Key meta-analyses cite 7-8 studies and 7-11 double-blind RCT comparisons, plus representative sham-controlled scalp-device RCTs from 2009, 2013, 2014, and 2017.

Evidence grade

moderate

Panel relevance

not-panel-replicable

Bottom line

Hair growth is a strong evidence category for dedicated scalp devices and a weak category for panel claims.

Consensus: LLLT appears to increase hair density in androgenetic alopecia, but the evidence is for scalp-specific caps, helmets, and combs, not broad body panels.

What the studies found

  • A 2019 meta-analysis reported significant hair density improvement across eight studies and 11 double-blind randomized controlled trials.
  • A 2021 home-device meta-analysis reported significant hair-density improvement across seven double-blind RCTs of FDA-cleared home-use devices.
  • A representative female androgenetic alopecia RCT reported a 51% hair-count increase versus sham after every-other-day 650 nm cap use for 17 weeks.
  • A 2009 multicenter HairMax LaserComb trial reported significantly greater terminal hair density versus sham at 26 weeks with no serious adverse events.
  • 2013 and 2014 visible red laser/LED scalp-device trials support the broader scalp-device evidence base in men and women.

Dosage and timing

Wavelengths650 nm
IrradianceNot settled
FluenceNot settled
Session timeDevice-specific; not interchangeable across caps, helmets, and combs.
FrequencyCommonly several sessions per week; one RCT used every-other-day treatment.
DurationMultiple months; one cited RCT used 17 weeks.
TimingNo strong consensus on time of day.
Treatment areaScalp, close to the hair follicles.
Device typesLaser caps, helmets, and comb-style LLLT devices.
NotesProtocol depends heavily on device geometry and scalp proximity.
  • The clearest wavelength signal is around 650 nm in scalp-device trials.
  • The most honest protocol guidance is to follow the tested cap/comb device protocol, not convert it casually to body-panel distance and time.
  • Evidence supports months-long consistency rather than occasional exposure.

Caveats

  • Do not present body panels as equivalent to FDA-cleared or trial-tested hair devices.
  • Pattern hair loss severity, sex, medication use, and baseline hair density can affect outcomes.
  • Long-term maintenance and combination therapy questions remain open.

Cited peer-reviewed sources

meta-analysis 7 included studies Evidence: moderate; direction: positive Panel relevance: not-panel-replicable Wavelengths: 650 nm Dose/timing: Varied by device and trial / Typically multiple months Area: Scalp Device: Home-use laser combs, caps, and helmet devices Source

Lueangarun S, Visutjindaporn P, Parcharoen Y, et al. Journal of Clinical and Aesthetic Dermatology. 2021.

This review focused on FDA-cleared home-use low-level light/laser devices for pattern hair loss.

Source

meta-analysis 8 included studies Evidence: moderate; direction: positive Panel relevance: not-panel-replicable Wavelengths: 650 nm Dose/timing: Varied; lower-frequency treatment subgroup performed better than high-frequency treatment subgroup / Short and long courses were both represented Area: Scalp Device: Low-level laser comb and helmet devices Source

Liu KH, Liu D, Chen YT, et al. Lasers in Medical Science. 2019.

A meta-analysis of adult androgenetic alopecia trials found increased hair density with LLLT versus sham.

Source

randomized-controlled-trial Study count not extracted Evidence: moderate; direction: positive Panel relevance: not-panel-replicable Wavelengths: 650 nm Dose/timing: Every other day / 17 weeks Area: Scalp Device: Laser diode cap Source

Friedman S, Schnoor P. Dermatologic Surgery. 2017.

A multicenter RCT tested a 650 nm laser cap-style device in healthy females with androgenetic alopecia.

Source

randomized-controlled-trial 110 participants Evidence: moderate; direction: positive Panel relevance: not-panel-replicable Wavelengths: 655 nm Dose/timing: 26 weeks Area: Scalp Device: Handheld laser comb that parts hair to deliver light to scalp Source

Leavitt M, Charles G, Heyman E, Michaels D. Clinical Drug Investigation. 2009.

This multicenter double-blind sham-device-controlled trial tested a handheld 655 nm HairMax LaserComb in men with androgenetic alopecia.

Source

randomized-controlled-trial Study count not extracted Evidence: moderate; direction: positive Panel relevance: not-panel-replicable Wavelengths: 655 nm Dose/timing: Not fully reported Area: Scalp Device: Visible red laser and LED scalp device Source

Lanzafame RJ, Blanche RR, Bodian AB, et al. Lasers in Surgery and Medicine. 2013.

A randomized sham-controlled study found that 655 nm red laser/LED scalp treatment significantly improved hair counts in men with androgenetic alopecia.

Source

randomized-controlled-trial Study count not extracted Evidence: moderate; direction: positive Panel relevance: not-panel-replicable Wavelengths: Not reported Dose/timing: Not fully reported Area: Scalp Device: Low-level laser hair-growth device Source

Jimenez JJ, Wikramanayake TC, Bergfeld W, et al. American Journal of Clinical Dermatology. 2014.

A multicenter randomized, sham-device-controlled, double-blind trial found low-level laser treatment may be effective for pattern hair loss in men and women.

Source

Last reviewed: 2026-06-15